LJPC Stock Price | La Jolla Pharmaceutical Co. Stock Quote (U.S.: Nasdaq)

0
149





La Jolla shares fall on CEO departure, clinical trial results

Shares of La Jolla Pharmaceutical Company fell 30% in premarket trading after it announced president and CEO George Tidmarsh had left the company and that the company plans to “re-evaluate its current operating plan” following mixed-results in two clinical studies. La Jolla said it discontinued one study evaluating its experimental treatment, LJPC-401, for iron overload in some patients with beta thalassemia over a lack of efficacy. A separate study testing LJPC-401 as a treatment for patients with hereditary hemochromatosis had met the primary endpoint in a Phase 2 study. La Jolla stock is down 40% year-to-date, while the S&P 500 is up 24%.








Source : MTV